HOME >> BIOLOGY >> NEWS
Two Yale graduate students to receive Howard Hughes Medical Institute fellowships

New Haven, Conn. -- The Howard Hughes Medical Institute (HHMI) today announced that of the six talented graduate students who will receive the Gilliam Graduate Fellowships for studies in the life sciences, two will attend Yale.

The late James H. Gilliam Jr., a charter Trustee of Howard Hughes Medical Institute (HHMI), spent a lifetime fostering diversity and opportunity in education and science. Created this year by HHMI to honor Gilliam's legacy, the fellowships provide support for Ph.D. studies in the life sciences to students including underrepresented minorities who participated in HHMI's Exceptional Research Opportunities (EXROP) undergraduate summer research program.

For the past two summers, EXROP has placed a group of outstanding minority and disadvantaged undergraduates in labs of HHMI investigators and professors. Their research projects ranged from identification of the cells in which lung cancer originates to investigation of the mechanism by which the human immunodeficiency virus (HIV) establishes and sustains latent infection in cells. This year's six Gilliam Fellows were selected from a pool of 84 EXROP students who were eligible to apply.

Imran Babar, a Native American/Asian earned a degree in biology at Carleton College in Northfield, Minnesota. He did his EXROP research with HHMI investigator Tyler Jacks at the Massachusetts Institute of Technology, working to discover the role of stem cells in lung tumor formation. He will carry out graduate study in molecular, cellular and developmental biology at Yale.

Meisha Bynoe was born and raised in the West Indies and earned a bachelor's degree in biology and music at MIT. She conducted research in the lab of HHMI investigator Richard Locksley at the University of California, San Francisco, where she helped develop assays to identify certain macrophages or immune system cells. She will enter Yale's graduate program in microbiology this fall.

"We are delighted tha
'"/>

Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
203-432-2157
Yale University
23-May-2005


Page: 1 2

Related biology news :

1. Undergraduate research shows leaderless honeybee organizing
2. Merck and AAAS announce 2007 winners of Outstanding Undergraduate Research Programs
3. UTSA awarded $900,000 NSF grant to support undergraduate scholars
4. Alaska graduate receives nations top dissertation honor
5. New textbook uses real disease outbreaks to teach undergraduate microbiology
6. HHMI awards $86.4 million for undergraduate science education
7. BC undergraduate wunderkind racks up five national awards for science research
8. Summer research programs for undergraduates evaluated nationally
9. HHMI awards $10 million to graduate programs that combine science and medicine
10. Merck and AAAS announce 2006 winners for Outstanding Undergraduate Research Programs
11. Undergraduate researcher turns up the heat on hibernation

Post Your Comments:
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... 25, 2014 Lawrence Livermore scientists Charles ... Reuters list of " The World's Most Influential Scientific ... the 3,000 researchers who were identified by analyzing citation ... who published the highest-impact work (2002-2012 and 2012-2013). The ... combustion modeling . , "This recognition is a ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
Cached News: